Supplement to Ramezani et al.

A web supplement to "Adherence with legislation and recommendations to make public the protocol and results of post‑authorisation studies registered with the European Medicines Agency: cross-sectional study".

PAS examined for protocol and results availability.
Name Studies registered Protocol uploaded Results uploaded
MAH not further specified 9

6 / 7

85.7%

5 / 7

71.4%
Sponsor unspecified 3

2 / 2

100%

2 / 2

100%
Name of primary lead investigator specified 1

0 / 1

0%

0 / 0

100%
No funding 38

18 / 31

58.1%

5 / 15

33.3%
Specified sponsor unclear 110

28 / 77

36.4%

20 / 46

43.5%
1A Pharma 1

0 / 1

0%

0 / 0

43.5%
AGB-Pharma 1

0 / 0

0%

0 / 0

43.5%
ALK-Abelló (ALK) 8

3 / 7

42.9%

2 / 4

50%
ANRS Maladies infectieuses émergentes (ANRS MIE) 1

0 / 0

42.9%

0 / 0

50%
AOP Orphan Pharmaceuticals 1

1 / 1

100%

0 / 0

50%
ARIAD Pharmaceuticals 1

1 / 1

100%

1 / 1

100%
Aarhus University (AU) 2

2 / 2

100%

0 / 1

0%
Aarne Koskelo Foundation 1

1 / 1

100%

0 / 1

0%
AbbVie 31

23 / 25

92%

9 / 9

100%
Abbott 4

4 / 4

100%

4 / 4

100%
Acadia Pharmaceuticals 1

1 / 1

100%

0 / 0

100%
Acarpia Farmaceutici 1

1 / 1

100%

1 / 1

100%
Accord Healthcare 3

1 / 3

33.3%

0 / 1

0%
Actavis 6

0 / 3

0%

1 / 2

50%
Actelion 9

2 / 9

22.2%

1 / 6

16.7%
Adamed 1

0 / 1

0%

0 / 0

16.7%
Addmedica 1

1 / 1

100%

1 / 1

100%
Advanced Accelerator Applications (AAA) 1

1 / 1

100%

0 / 0

100%
Advanz Pharma Switzerland 1

1 / 1

100%

1 / 1

100%
Aegerion Pharmaceuticals 2

0 / 0

100%

0 / 0

100%
Aetion 2

1 / 1

100%

1 / 1

100%
Agence nationale de sécurité du médicament et des produits de santé (ANSM) 12

1 / 11

9.1%

0 / 7

0%
Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 6

2 / 3

66.7%

1 / 1

100%
Agencia Estatal de Investigación (AEI) 1

0 / 1

0%

0 / 0

100%
Agency for Health and Social Care of Emilia-Romagna (RER-ASSR) 1

0 / 1

0%

0 / 0

100%
Agency for Medicinal Products and Medical Devices (HALMED) 2

0 / 0

0%

0 / 0

100%
Agenzia Italiana del Farmaco (AIFA) 6

3 / 6

50%

1 / 5

20%
Agenzia Regionale di Sanità Toscana (ARS Toscana) 1

0 / 1

0%

0 / 0

20%
Agenzia regionale di sanità della Toscana (ARS) 5

5 / 5

100%

2 / 3

66.7%
Aimmune Therapeutics 1

0 / 0

100%

0 / 0

66.7%
Aimmune Therapeutics Ireland 1

0 / 0

100%

0 / 0

66.7%
Aimmune Therapeutics US 1

0 / 1

0%

0 / 0

66.7%
Akcea Therapeutics 4

0 / 0

0%

0 / 0

66.7%
Albireo Pharma 1

0 / 1

0%

0 / 0

66.7%
Alcon 4

2 / 4

50%

2 / 4

50%
Alexion Pharmaceuticals 7

5 / 7

71.4%

0 / 1

0%
Alexza Pharmaceuticals 2

0 / 1

0%

0 / 0

0%
Alimera Sciences 1

1 / 1

100%

1 / 1

100%
Alkem Laboratories 1

1 / 1

100%

0 / 0

100%
Alkem Laboratories US 1

1 / 1

100%

0 / 0

100%
Allergan 20

19 / 20

95%

14 / 14

100%
Almirall 6

3 / 6

50%

1 / 4

25%
Almirall Hermal Germany 3

0 / 0

50%

0 / 0

25%
Alnylam 5

0 / 3

0%

0 / 0

25%
Alvogen 1

1 / 1

100%

0 / 0

25%
Alzheimer's Society 4

0 / 3

0%

1 / 1

100%
Amgen 143

101 / 137

73.7%

98 / 103

95.1%
Amgen Algeria 1

0 / 0

73.7%

0 / 0

95.1%
Amgen Turkey 1

1 / 1

100%

0 / 0

95.1%
Amicus Therapeutics 2

0 / 1

0%

0 / 0

95.1%
Amicus Therapeutics UK 1

0 / 1

0%

0 / 0

95.1%
Amryt Pharma 1

0 / 1

0%

0 / 0

95.1%
Angelini Pharma 2

1 / 2

50%

1 / 1

100%
Angelini Pharma Austria 1

0 / 1

0%

0 / 0

100%
Angelini Pharma Czechia 1

0 / 1

0%

1 / 1

100%
Angenerico 1

1 / 1

100%

1 / 1

100%
Apotex 1

1 / 1

100%

0 / 0

100%
Aptalis 3

3 / 3

100%

3 / 3

100%
Ares Trading 1

0 / 1

0%

0 / 0

100%
Aristo Pharma 2

1 / 2

50%

0 / 0

100%
Arnold Ventures 1

0 / 0

50%

0 / 0

100%
Arrow Generiques 1

1 / 1

100%

1 / 1

100%
Ascendis Pharma 1

0 / 1

0%

0 / 0

100%
Aspen Pharmacare 1

1 / 1

100%

0 / 0

100%
Assistance publique – Hôpitaux de Marseille (AP-HM) 1

0 / 1

0%

0 / 0

100%
Association for Innovation and Biomedical Research on Light and Image (AIBILI) 4

1 / 2

50%

0 / 1

0%
Association française des centres régionaux de Pharmacovigilance (ACRPV) 1

1 / 1

100%

0 / 0

0%
Astellas Pharma 14

9 / 13

69.2%

10 / 13

76.9%
Astellas Pharma Europe 9

5 / 7

71.4%

3 / 6

50%
Astellas Pharma Singapore 1

1 / 1

100%

0 / 1

0%
Asthma UK 2

1 / 1

100%

0 / 0

0%
AstraZeneca 95

52 / 80

65%

24 / 45

53.3%
AstraZeneca Australia 1

0 / 1

0%

0 / 0

53.3%
AstraZeneca Canada 1

1 / 1

100%

1 / 1

100%
AstraZeneca Nordic Baltic 4

3 / 3

100%

2 / 3

66.7%
AstraZeneca UK 2

0 / 1

0%

0 / 0

66.7%
Avextra Pharma 3

0 / 3

0%

0 / 2

0%
B. Braun 2

1 / 2

50%

2 / 2

100%
Baxalta 9

8 / 9

88.9%

8 / 8

100%
Baxter 2

2 / 2

100%

2 / 2

100%
Bayer 75

68 / 73

93.2%

59 / 61

96.7%
Beca Mutual Médica 1

0 / 1

0%

0 / 0

96.7%
BeiGene 1

0 / 1

0%

0 / 0

96.7%
Beijing Natural Science Foundation (BJNSF) 1

0 / 1

0%

0 / 1

0%
Berlin Institute of Health (BIH) 1

0 / 0

0%

0 / 0

0%
Best Care Consulting (BCC) 2

0 / 1

0%

0 / 0

0%
Bill & Melinda Gates Foundation (BMGF) 2

1 / 1

100%

0 / 1

0%
Bio Industrial Strategic Technology Development Program 1

0 / 0

100%

0 / 0

0%
BioCryst 1

0 / 0

100%

0 / 0

0%
BioMarin 13

2 / 11

18.2%

1 / 3

33.3%
Biocodex 1

0 / 1

0%

0 / 0

33.3%
Biogaran 2

1 / 2

50%

1 / 2

50%
Biogen 24

14 / 21

66.7%

13 / 14

92.9%
Biogen France 1

0 / 1

0%

0 / 1

0%
Biogen Netherlands 1

0 / 0

0%

0 / 0

0%
Biohaven 2

2 / 2

100%

0 / 0

0%
Bioiberica 2

2 / 2

100%

0 / 0

0%
Biomedical Research Foundation (BRF) 1

0 / 0

100%

0 / 0

0%
Bioprojet 1

0 / 1

0%

0 / 0

0%
Biotest 9

1 / 9

11.1%

2 / 7

28.6%
Blueprint Medicines Netherlands 1

0 / 0

11.1%

0 / 0

28.6%
Boehringer Ingelheilm 1

1 / 1

100%

0 / 1

0%
Boehringer Ingelheim 122

34 / 93

36.6%

29 / 51

56.9%
Boehringer Ingelheim China 7

1 / 3

33.3%

1 / 2

50%
Boehringer Ingelheim France 1

0 / 1

0%

0 / 1

0%
Boehringer Ingelheim Greece 5

1 / 5

20%

0 / 1

0%
Boehringer Ingelheim India 1

0 / 0

20%

0 / 0

0%
Boehringer Ingelheim Italia 1

0 / 1

0%

0 / 0

0%
Boehringer Ingelheim Korea 2

0 / 1

0%

0 / 0

0%
Boehringer Ingelheim Spain 6

0 / 5

0%

2 / 5

40%
Boehringer Ingelheim Switzerland 1

0 / 1

0%

0 / 0

40%
Boehringer Ingelheim Taiwan 1

0 / 0

0%

0 / 0

40%
Boston Scientific 1

0 / 1

0%

0 / 0

40%
Bracco Imaging 1

1 / 1

100%

1 / 1

100%
Brigham and Women's Hospital 1

0 / 0

100%

0 / 0

100%
Bristol-Myers Squibb (BMS) 39

12 / 32

37.5%

9 / 19

47.4%
British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) 1

1 / 1

100%

0 / 0

47.4%
British Society for Rheumatology (BSR) 1

0 / 1

0%

0 / 0

47.4%
Bror Hjerpstedts Foundation 1

0 / 1

0%

0 / 0

47.4%
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) 5

0 / 4

0%

1 / 2

50%
Bundesministerium für Bildung und Forschung (BMBF) 3

0 / 2

0%

0 / 0

50%
Bundesministerium für Gesundheit (BMG) 2

1 / 2

50%

0 / 1

0%
CHU de Martinique (CHUM) 1

1 / 1

100%

0 / 0

0%
CHU de Nantes 2

0 / 2

0%

0 / 2

0%
CHU de Toulouse 2

1 / 1

100%

1 / 1

100%
CNX Therapeutics 1

1 / 1

100%

1 / 1

100%
CO.DON 1

1 / 1

100%

1 / 1

100%
COOPER Pharmaceuticals 1

0 / 0

100%

0 / 0

100%
CSL 1

0 / 1

0%

0 / 0

100%
CSL Behring 4

1 / 2

50%

0 / 1

0%
CSL Seqirus 5

4 / 5

80%

4 / 5

80%
CSL Vifor 3

0 / 3

0%

2 / 2

100%
CSL Vifor UK 1

0 / 0

0%

0 / 0

100%
Caisse Nationale d’Assurance Maladie des Travailleurs Salariés (CNAMTS) 2

0 / 2

0%

0 / 2

0%
Canadian Agency for Drugs and Technologies in Health (CADTH) 2

0 / 1

0%

0 / 0

0%
Canadian Institutes of Health Research (CIHR) 1

0 / 1

0%

0 / 0

0%
Canadian Respiratory Research Network (CRRN) 1

0 / 1

0%

0 / 1

0%
Cancer Research UK 1

1 / 1

100%

0 / 0

0%
Canterbury District Health Board (CDHB) 1

1 / 1

100%

0 / 0

0%
Catalan Health Service 1

0 / 1

0%

1 / 1

100%
Celgene 9

1 / 9

11.1%

1 / 4

25%
Celltrion 6

4 / 6

66.7%

1 / 1

100%
Celltrion Hungary 2

1 / 1

100%

0 / 0

100%
Centre for Health Research & Evaluation (CEFAR) 1

0 / 1

0%

0 / 0

100%
Centre hospitalier universitaire vaudois (CHUV) 1

1 / 1

100%

0 / 1

0%
Centro de Estudios sobre la Seguridad de los Medicamentos (CESME) 1

0 / 1

0%

0 / 0

0%
Cerus 1

1 / 1

100%

0 / 0

0%
Charité - Universitätsmedizin Berlin 1

0 / 0

100%

0 / 0

0%
Chief Scientist Office Scotland 1

0 / 0

100%

0 / 0

0%
Chiesi Farmaceutici 17

6 / 14

42.9%

1 / 3

33.3%
Chiesi Farmaceutici Italy 1

0 / 0

42.9%

0 / 0

33.3%
Chiesi Farmaceutici Netherlands 1

0 / 1

0%

0 / 0

33.3%
Christian Doppler Research Association (CDG) 1

0 / 0

0%

0 / 0

33.3%
Chugai Pharmaceutical 2

2 / 2

100%

1 / 2

50%
Clarendon Fund 1

1 / 1

100%

0 / 0

50%
Clinical Practice Research Datalink (CPRD) 1

0 / 1

0%

0 / 1

0%
Clinigen Group 1

0 / 0

0%

0 / 0

0%
Clinuvel 3

0 / 2

0%

0 / 0

0%
Colgate-Palmolive 1

1 / 1

100%

0 / 1

0%
Colonis Pharma 1

0 / 1

0%

0 / 0

0%
ConcePTION 9

4 / 8

50%

0 / 0

0%
Congrès Français de Psychiatrie (CFP) 1

1 / 1

100%

0 / 0

0%
Consejería de Economía, Innovación, Ciencia y Empleo (CEICE) 1

0 / 1

0%

0 / 0

0%
Copenhagen Centre for Regulatory Science (CORS) 1

1 / 1

100%

1 / 1

100%
Correvio Pharma 1

0 / 1

0%

0 / 1

0%
Crucell 1

1 / 1

100%

1 / 1

100%
CureVac 1

0 / 1

0%

0 / 0

100%
Currax Pharmaceuticals 3

2 / 2

100%

1 / 1

100%
Cyathus Exquirere 1

1 / 1

100%

0 / 1

0%
Czech Medical Association of J. E. Purkyně (CzMA) 1

0 / 1

0%

0 / 0

0%
DOC Generici 1

1 / 1

100%

1 / 1

100%
DR. KADE Health Care 1

0 / 1

0%

0 / 0

100%
Daiichi Sankyō 13

6 / 12

50%

7 / 9

77.8%
Daleco Pharma 1

0 / 1

0%

0 / 0

77.8%
Danish Cardiovascular Academy (DCAcademy) 1

0 / 1

0%

0 / 0

77.8%
Danish Medicines Agency 1

0 / 1

0%

0 / 0

77.8%
Demo Α.B.E.Ε. 1

0 / 0

0%

0 / 0

77.8%
Departament de Salut [Catalonia] 2

1 / 1

100%

0 / 0

77.8%
Dermapharm 1

0 / 1

0%

0 / 0

77.8%
Deutsche Gesellschaft für Schmerzmedizin (DGS) 9

0 / 9

0%

0 / 9

0%
Deutsche Schmerzliga (DSL) 1

0 / 1

0%

0 / 1

0%
Deutsches Arzneiprüfungsinstitut (DAPI) 1

0 / 1

0%

1 / 1

100%
Diabetes UK 1

0 / 0

0%

0 / 0

100%
Direction générale de l'Offre de soins (DGOS) 3

2 / 3

66.7%

2 / 2

100%
Director-General Health and Social Care 1

1 / 1

100%

0 / 0

100%
Directorate-General for Health and Consumers (DG SANCO) 1

0 / 1

0%

0 / 1

0%
Domperidone Collaboration Study Group 2

2 / 2

100%

2 / 2

100%
Dompé Farmaceutici 3

2 / 3

66.7%

2 / 3

66.7%
Dresden University of Technology (TU Dresden) 1

0 / 1

0%

1 / 1

100%
Dynavax Technologies 3

2 / 3

66.7%

0 / 2

0%
EG Labo 2

1 / 2

50%

1 / 2

50%
EG Stada 2

2 / 2

100%

1 / 2

50%
ELPEN Pharmaceutical 1

1 / 1

100%

0 / 0

50%
EU4Health 1

0 / 1

0%

0 / 0

50%
EUSA Pharma 2

1 / 2

50%

1 / 1

100%
EffRx Pharmaceuticals 1

0 / 0

50%

0 / 0

100%
Eisai 10

1 / 10

10%

4 / 8

50%
Eli Lilly 92

50 / 70

71.4%

38 / 45

84.4%
Eli Lilly Italy 1

1 / 1

100%

1 / 1

100%
Eli Lilly Japan 11

2 / 6

33.3%

0 / 3

0%
Eli Lilly Sweden 1

0 / 1

0%

0 / 0

0%
Elizabeth Blackwell Institute for Health Research 1

0 / 1

0%

0 / 0

0%
Endoceutics 1

0 / 1

0%

0 / 1

0%
Epifarma 1

1 / 1

100%

1 / 1

100%
Erasmus Medical Center (EMC) 1

0 / 0

100%

0 / 0

100%
Erik and Susanna Olesen's Charitable Fund 1

1 / 1

100%

0 / 1

0%
Estetra 1

0 / 0

100%

0 / 0

0%
Esteve Pharmaceuticals 1

0 / 1

0%

0 / 0

0%
European Commission (EC) 7

5 / 5

100%

3 / 3

100%
European Federation of Pharmaceutical Industries and Associations (EFPIA) 5

3 / 3

100%

0 / 1

0%
European Health Data & Evidence Network (EHDEN) 8

5 / 5

100%

0 / 3

0%
European Medicines Agency (EMA) 157

100 / 155

64.5%

106 / 135

78.5%
European Network of Teratology Information Services (ENTIS) 2

2 / 2

100%

0 / 1

0%
European Regional Development Fund (ERDF) 1

1 / 1

100%

0 / 0

0%
Evolus 1

0 / 0

100%

0 / 0

0%
Exeltis 1

1 / 1

100%

0 / 0

0%
F. Hoffmann-La Roche 58

38 / 57

66.7%

19 / 34

55.9%
F. Hoffmann-La Roche India 1

0 / 1

0%

0 / 0

55.9%
Farmaceutici CABER 1

1 / 1

100%

1 / 1

100%
Farmitalia 1

1 / 1

100%

0 / 0

100%
Farr Institute 1

0 / 1

0%

0 / 0

100%
Federal Office of Public Health (FOPH) 1

1 / 1

100%

0 / 1

0%
Ferrer 2

1 / 2

50%

0 / 1

0%
Ferring Pharmaceuticals 2

1 / 2

50%

0 / 1

0%
Finnish Foundation for Cardiovascular Research 1

1 / 1

100%

0 / 1

0%
Finnish Medicines Agency (Fimea) 2

2 / 2

100%

2 / 2

100%
Fluart Innovative Vaccines 10

6 / 10

60%

0 / 9

0%
Fondation Bordeaux Université 1

1 / 1

100%

1 / 1

100%
Food and Drug Administration (FDA) 2

1 / 2

50%

0 / 0

100%
Forest Laboratories UK 1

0 / 1

0%

0 / 1

0%
Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO) 3

3 / 3

100%

0 / 2

0%
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) 1

0 / 0

100%

0 / 0

0%
Fresenius Kabi Germany 2

2 / 2

100%

2 / 2

100%
Fundación Iniciativa Para las Neurociencias (FINCE) 1

0 / 0

100%

0 / 0

100%
Fundación Mutua Madrileña 1

1 / 1

100%

0 / 0

100%
Fundação para a Ciência e a Tecnologia (FCT) 4

0 / 3

0%

0 / 2

0%
GE Healthcare 3

3 / 3

100%

0 / 2

0%
GW Pharmaceuticals 2

0 / 0

100%

0 / 0

0%
Galapagos 7

4 / 7

57.1%

1 / 1

100%
Galapagos Italy 1

1 / 1

100%

1 / 1

100%
Galderma Korea 2

0 / 1

0%

0 / 0

100%
Gavi, the Vaccine Alliance 1

0 / 1

0%

0 / 0

100%
Gedeon Richter 5

3 / 5

60%

1 / 2

50%
Genentech 6

1 / 3

33.3%

0 / 0

50%
General Practitioners Research Institute (GPRI) 2

0 / 2

0%

0 / 0

50%
Generis Farmaceutica 1

1 / 1

100%

1 / 1

100%
Genome Canada 1

0 / 1

0%

0 / 1

0%
Genzyme 16

15 / 15

100%

7 / 9

77.8%
Gilead Sciences 35

33 / 35

94.3%

26 / 30

86.7%
Gilead Sciences Ireland 1

1 / 1

100%

0 / 1

0%
GlaxoSmithKline (GSK) 101

81 / 95

85.3%

44 / 63

69.8%
GlaxoSmithKline Biologicals (GSK Bio) 14

10 / 14

71.4%

9 / 12

75%
GlaxoSmithKline Consumer Healthcare (GSK Consumer Healthcare) 1

1 / 1

100%

0 / 1

0%
GlaxoSmithKline Vaccines (GSK Vaccines) 2

2 / 2

100%

1 / 2

50%
Global Fund 1

0 / 1

0%

0 / 0

50%
Government of Navarre 4

1 / 1

100%

0 / 1

0%
Grifols 2

1 / 1

100%

1 / 1

100%
Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH) 1

1 / 1

100%

1 / 1

100%
Grünenthal 10

1 / 9

11.1%

2 / 8

25%
Guerbet 1

0 / 0

11.1%

0 / 0

25%
Gynial 1

0 / 1

0%

0 / 0

25%
H. Lundbeck 5

4 / 5

80%

0 / 1

0%
HRA Pharma 1

1 / 1

100%

1 / 1

100%
HRA Pharma Rare Diseases 1

0 / 1

0%

0 / 0

100%
Hannover Medical School (MHH) 2

0 / 1

0%

0 / 0

100%
Harvey Walsh 1

1 / 1

100%

0 / 1

0%
Health Data Hub 1

0 / 0

100%

0 / 0

0%
Health Department Xàtiva-Ontinyent 1

0 / 1

0%

0 / 1

0%
Health Insurance Review and Assessment Service (HIRA) 2

1 / 1

100%

0 / 1

0%
Health Research Board (HRB) 1

1 / 1

100%

0 / 0

0%
Heaton 1

0 / 1

0%

0 / 0

0%
Helm AG 1

1 / 1

100%

0 / 0

0%
Help A.B.E.E. 1

0 / 0

100%

0 / 0

0%
Helsinn Healthcare 2

0 / 2

0%

0 / 2

0%
Hexal AG 3

1 / 3

33.3%

1 / 1

100%
Hisamitsu Pharmaceutical 1

1 / 1

100%

0 / 1

0%
Holostem Terapie Avanzate 1

0 / 1

0%

0 / 0

0%
Horizon 2020 3

1 / 3

33.3%

1 / 1

100%
Horizon Europe 1

1 / 1

100%

0 / 0

100%
Horizon Therapeutics 1

0 / 0

100%

0 / 0

100%
Hormosan Pharma 2

1 / 2

50%

1 / 1

100%
Hospices Civils de Lyon (HCL) 1

0 / 1

0%

1 / 1

100%
Hospira UK 1

1 / 1

100%

1 / 1

100%
Hospital District of Helsinki and Uusimaa (HUS) 1

1 / 1

100%

0 / 1

0%
Hospital Universitario La Paz (HULP) 1

0 / 0

100%

0 / 0

0%
Hospital Universitario Puerta de Hierro Majadahonda (HUPHM) 1

1 / 1

100%

0 / 1

0%
Hospital Universitario San Ignacio (HUSI) 1

0 / 0

100%

0 / 0

0%
Hospital of Lithuanian University of Health Sciences Kauno klinikos (LSMU Kauno Klinikos) 1

0 / 0

100%

0 / 0

0%
IBSA Institut Biochimique 1

0 / 1

0%

0 / 1

0%
IDIAP Jordi Gol (IDIAPJGol) 8

4 / 4

100%

1 / 4

25%
IIS Biobizkaia 2

2 / 2

100%

1 / 2

50%
IOMED 1

1 / 1

100%

0 / 1

0%
IQVIA 3

1 / 3

33.3%

0 / 0

0%
Immedica Pharma 1

1 / 1

100%

1 / 1

100%
Immunocore Ireland 1

1 / 1

100%

0 / 0

100%
Infarmed 1

0 / 0

100%

0 / 0

100%
Innovationsausschuss 2

2 / 2

100%

0 / 2

0%
Innovative Medicines Initiative (IMI) 22

17 / 17

100%

9 / 11

81.8%
Inselspital, Universitätsspital Bern 1

0 / 1

0%

0 / 0

81.8%
Institut Català de la Salut (ICS) 1

0 / 0

0%

0 / 0

81.8%
Institut de Recherches International Servier (IRIS) 2

1 / 2

50%

0 / 1

0%
Institut pour la Recherche en Santé Publique (IReSP) 1

1 / 1

100%

1 / 1

100%
Institute for Neurosciences, Algesiology and Pediatrics (IFNAP) 10

0 / 7

0%

0 / 6

0%
Institute for Pharmacoeconomics and Pharmaceutical Logistics (IPAM) 1

0 / 0

0%

0 / 0

0%
Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA) 1

1 / 1

100%

0 / 0

0%
Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) 1

0 / 1

0%

0 / 0

0%
Instituto de Salud Carlos III (ISCIII) 12

5 / 8

62.5%

1 / 1

100%
International Primary Care Respiratory Group (IPCRG) 2

1 / 2

50%

0 / 1

0%
International Society for Pharmacoepidemiology (ISPE) 1

1 / 1

100%

0 / 0

0%
Ipsen 19

11 / 19

57.9%

13 / 16

81.3%
Irish Cancer Society 1

1 / 1

100%

1 / 1

100%
Istituto Biochimico Italiano Giovanni Lorenzini (IBI) 1

1 / 1

100%

0 / 1

0%
Istituto per lo studio, la prevenzione e la rete oncologica (ISPRO) 1

1 / 1

100%

0 / 0

0%
Italfarmaco 1

1 / 1

100%

0 / 1

0%
Italian Medicines Agency (AIFA) 7

0 / 5

0%

2 / 3

66.7%
JSC Grindeks 1

1 / 1

100%

0 / 1

0%
Janssen 20

7 / 17

41.2%

2 / 6

33.3%
Janssen Biotech 1

0 / 1

0%

0 / 0

33.3%
Janssen Cilag 13

5 / 13

38.5%

5 / 9

55.6%
Janssen Cilag Sweden 1

0 / 1

0%

0 / 1

0%
Janssen France 1

1 / 1

100%

0 / 1

0%
Janssen Ireland 1

1 / 1

100%

0 / 1

0%
Janssen R&D 17

3 / 15

20%

3 / 12

25%
Jazz Pharmaceuticals 2

1 / 1

100%

0 / 1

0%
Jenapharm 1

0 / 1

0%

0 / 0

0%
Johnson & Johnson (J&J) 11

8 / 8

100%

3 / 5

60%
Kindeva Drug Delivery 1

1 / 1

100%

0 / 1

0%
Kite 3

2 / 2

100%

0 / 0

0%
Kooperation Phytopharmaka 1

1 / 1

100%

1 / 1

100%
Korangi - Produtos Farmacêuticos 1

1 / 1

100%

1 / 1

100%
Krka d.d. 2

0 / 1

0%

0 / 0

100%
Kwizda Pharma 1

0 / 1

0%

0 / 0

100%
Kyowa Kirin 7

4 / 5

80%

3 / 4

75%
Kéry Pharma 1

0 / 1

0%

0 / 0

75%
LEO Pharma 7

2 / 6

33.3%

3 / 4

75%
LEO Pharma Korea 1

0 / 1

0%

0 / 0

75%
LETI Pharma 1

0 / 1

0%

0 / 0

75%
LFB Biomedicaments 1

1 / 1

100%

0 / 1

0%
LFB Biotechnologies 2

0 / 2

0%

0 / 0

0%
LFB Group 1

1 / 1

100%

1 / 1

100%
Laboratoire Arrow 1

0 / 1

0%

0 / 1

0%
Laboratoire Cristers 1

1 / 1

100%

1 / 1

100%
Laboratoires Pierre Fabre 3

1 / 3

33.3%

0 / 2

0%
Laboratoires Servier 6

4 / 6

66.7%

4 / 5

80%
Laboratorio Farmaceutico CT 1

1 / 1

100%

1 / 1

100%
Laboratorios Alter 1

1 / 1

100%

1 / 1

100%
Leadiant Biosciences 4

4 / 4

100%

3 / 3

100%
Legend Biotech US 1

0 / 1

0%

0 / 0

100%
Lithuanian University of Health Sciences (LSMU) 1

0 / 0

0%

0 / 0

100%
Lundbeck 1

1 / 1

100%

1 / 1

100%
Lundbeck Foundation 1

1 / 1

100%

0 / 0

100%
Lundbeck France 1

0 / 1

0%

0 / 1

0%
Lupin Pharma 4

3 / 4

75%

3 / 3

100%
MDM S.p.A. 1

1 / 1

100%

1 / 1

100%
MEDA Pharma 6

0 / 6

0%

1 / 5

20%
MEDA Pharma Australia 1

0 / 0

0%

0 / 0

20%
MEDICE Health Family 3

2 / 2

100%

2 / 2

100%
MEMO Research 1

0 / 1

0%

0 / 0

100%
Maritime SPOR SUPPORT Unit (MSSU) 1

0 / 1

0%

0 / 0

100%
Maxwellia 1

1 / 1

100%

1 / 1

100%
MedImmune 4

3 / 4

75%

2 / 3

66.7%
MediWound 1

1 / 1

100%

1 / 1

100%
MediWound Germany 2

1 / 2

50%

2 / 2

100%
Medical Developments International (MDI) 2

0 / 2

0%

0 / 1

0%
Medical Device Innovation Consortium (MDIC) 1

1 / 1

100%

0 / 0

0%
Medical Products Agency (MPA) 1

1 / 1

100%

0 / 0

0%
Medical Research Council (MRC) 6

3 / 4

75%

0 / 1

0%
Medicines Evaluation Board (MEB) 1

0 / 1

0%

0 / 0

0%
Medinfar Group 1

0 / 1

0%

0 / 0

0%
Medtronic BioPharma 1

1 / 1

100%

1 / 1

100%
Menarini 1

1 / 1

100%

0 / 1

0%
Menarini Luxembourg 1

1 / 1

100%

1 / 1

100%
Merck Serono 8

7 / 8

87.5%

2 / 5

40%
Merck Serono / EMD Serono 2

0 / 2

0%

0 / 2

0%
Merck Sharp & Dohme (MSD) 97

52 / 84

61.9%

39 / 56

69.6%
Merck Sharp & Dohme China (MSD China) 6

0 / 3

0%

0 / 0

69.6%
Merck Sharp & Dohme France (MSD France) 2

0 / 2

0%

0 / 2

0%
Merckle 1

0 / 1

0%

0 / 1

0%
Ministero dell'Università e della Ricerca (MUR) 1

1 / 1

100%

0 / 0

0%
Ministery of Health [Netherlands] 1

0 / 1

0%

0 / 0

0%
Ministry of Education, Youth and Sports (MEYS / MŠMT) 1

1 / 1

100%

0 / 0

0%
Ministry of Health [Czech Republic] 2

1 / 1

100%

0 / 0

0%
Ministry of Health [Spain] 2

1 / 2

50%

0 / 0

0%
Ministry of Health and Welfare (MOHW) 1

0 / 0

50%

0 / 0

0%
Ministry of Health, Czech Republic – conceptual development of research organization (MH CZ - DRO) 1

0 / 1

0%

0 / 1

0%
Ministry of Health, Welfare and Sport (VWS) 2

0 / 1

0%

0 / 0

0%
Ministère du Travail, de la Santé et des Solidarités 4

0 / 4

0%

0 / 0

0%
Mithra Pharmaceuticals 1

0 / 1

0%

0 / 0

0%
Mitsubishi Tanabe Pharma 1

0 / 0

0%

0 / 0

0%
Moderna 9

3 / 9

33.3%

0 / 0

0%
Molecular, cellular and clinical approach to healthy ageing (ENOCH) 1

1 / 1

100%

0 / 0

0%
Monash University 1

1 / 1

100%

1 / 1

100%
Morningside Healthcare 1

0 / 1

0%

0 / 1

0%
Motol University Hospital (FNM) 1

1 / 1

100%

0 / 0

0%
Mundipharma 15

4 / 15

26.7%

3 / 7

42.9%
Mylan 11

4 / 9

44.4%

3 / 4

75%
Mylan Ireland 1

1 / 1

100%

0 / 0

75%
NIHR School for Primary Care Research 1

0 / 0

100%

0 / 0

75%
Napp Pharmaceuticals 3

3 / 3

100%

3 / 3

100%
National Autonomous University of Mexico (UNAM) 1

0 / 1

0%

1 / 1

100%
National Center for Advancing Translational Sciences (NCATS) 1

0 / 0

0%

0 / 0

100%
National Clinical Research Center for Musculoskeletal Diseases 1

1 / 1

100%

0 / 1

0%
National Health and Medical Research Council (NHMRC) 2

0 / 0

100%

0 / 0

0%
National Institute for Health and Care Research (NIHR) 5

2 / 4

50%

0 / 1

0%
National Institute for Health and Care Research Health Technology Assessment (NIHR HTA) 1

0 / 1

0%

0 / 0

0%
National Institute of Health and Welfare 1

1 / 1

100%

1 / 1

100%
National Institute of Mental Health (NIMH) 2

0 / 1

0%

0 / 0

100%
National Institute on Aging (NIA) 3

3 / 3

100%

0 / 2

0%
National Institutes of Health (NIH) 5

4 / 5

80%

1 / 1

100%
NeoTract 1

0 / 1

0%

0 / 0

100%
Nippon Boehringer Ingelheim (NBI) 22

7 / 18

38.9%

0 / 12

0%
Nordic Group 1

1 / 1

100%

1 / 1

100%
Norgine 1

0 / 1

0%

0 / 1

0%
Notable Labs 1

0 / 1

0%

0 / 0

0%
Novartis 77

58 / 66

87.9%

38 / 46

82.6%
Novartis Gene Therapies 1

1 / 1

100%

0 / 0

82.6%
Novavax 5

1 / 4

25%

0 / 0

82.6%
Novo Nordisk 22

21 / 22

95.5%

12 / 12

100%
Novo Nordisk Finland 1

0 / 1

0%

0 / 1

0%
Novo Nordisk Scandinavia 1

0 / 1

0%

0 / 0

0%
Novocol Pharma 1

1 / 1

100%

1 / 1

100%
Nära vård och hälsa, Region Uppsala (NVP, Region Uppsala) 1

0 / 1

0%

0 / 0

100%
O. Meany Medical Data & Project Management (O. Meany MD&PM) 4

0 / 3

0%

0 / 3

0%
OXON Epidemiology 3

0 / 3

0%

0 / 0

0%
Observational & Pragmatic Research Institute (OPRI) 10

1 / 2

50%

0 / 1

0%
Observational & Pragmatic Research Institute UK (OPRI UK) 1

0 / 0

50%

0 / 0

0%
Observational Health Data Sciences and Informatics (OHDSI) 1

0 / 1

0%

0 / 0

0%
Octapharma 5

1 / 5

20%

1 / 4

25%
Olomouc University Hospital 1

1 / 1

100%

0 / 0

25%
Optimum Patient Care (OPC) 3

0 / 1

0%

0 / 0

25%
Optimum Patient Care Australia (OPC Australia) 3

0 / 3

0%

0 / 0

25%
Optimum Patient Care Global (OPCG) 17

5 / 12

41.7%

2 / 5

40%
OptumLabs 1

0 / 0

41.7%

0 / 0

40%
Oral Retinoids Marketing Authorisation Holder Consortium (Oral Retinoids MAH Consortium) 1

1 / 1

100%

1 / 1

100%
Orchard Therapeutics 3

1 / 3

33.3%

0 / 1

0%
Orexigen Therapeutics 2

1 / 1

100%

1 / 1

100%
Organon 1

0 / 0

100%

0 / 0

100%
Orifarm 1

1 / 1

100%

1 / 1

100%
Orion Corporation 3

1 / 3

33.3%

1 / 3

33.3%
Orion Corporation Poland 1

1 / 1

100%

1 / 1

100%
Orphan Europe 1

0 / 1

0%

1 / 1

100%
Ospedale "Santa Maria della Misericordia" di Perugia 1

0 / 0

0%

0 / 0

100%
Otsuka Novel Products (ONPG) 1

1 / 1

100%

1 / 1

100%
Otsuka Pharmaceutical 4

2 / 4

50%

3 / 3

100%
P95 2

0 / 2

0%

1 / 2

50%
PTC Therapeutics 2

0 / 2

0%

0 / 0

50%
Pain Technologies and Clinical Monitoring 1

0 / 1

0%

0 / 0

50%
Paris Diderot University (Paris 7) 1

0 / 1

0%

0 / 0

50%
Pascoe 1

0 / 1

0%

0 / 0

50%
Paul-Ehrlich-Institut (PEI) 1

0 / 0

0%

0 / 0

50%
Pearl Therapeutics 1

1 / 1

100%

0 / 0

50%
Petrovax Pharm 1

1 / 1

100%

1 / 1

100%
Pfizer 176

119 / 142

83.8%

83 / 91

91.2%
Pfizer Austria 1

0 / 1

0%

0 / 0

91.2%
Pfizer Hungary 1

0 / 0

0%

0 / 0

91.2%
Pfizer Japan 1

0 / 0

0%

0 / 0

91.2%
Pfizer Turkey 1

1 / 1

100%

1 / 1

100%
Pharma Industry Finland (PIF) 1

1 / 1

100%

1 / 1

100%
Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) 1

1 / 1

100%

0 / 1

0%
Pharmacosmos 2

0 / 2

0%

0 / 2

0%
Pharmanovia 1

0 / 0

0%

0 / 0

0%
Pharmaxis 1

1 / 1

100%

1 / 1

100%
Pharming Group 1

0 / 1

0%

0 / 0

100%
Phytopharm Klęka 1

1 / 1

100%

1 / 1

100%
Piramal Group 2

0 / 2

0%

0 / 2

0%
Pla Estratègic de Recerca i Innovació en Salut (PERIS) 1

0 / 0

0%

0 / 0

0%
PregLem 1

1 / 1

100%

0 / 0

0%
Pregistry 1

0 / 0

100%

0 / 0

0%
Program for Appropriate Technology in Health (PATH) 1

1 / 1

100%

0 / 1

0%
Programa públic d'analítica de dades per a la recerca i la innovació en salut (PADRIS) 1

0 / 0

100%

0 / 0

0%
Programme Hospitalier de Recherche Clinique (PHRC) 9

0 / 9

0%

0 / 6

0%
Programme de Recherche Médico-Economique (PRME) 1

0 / 1

0%

0 / 1

0%
Propius Single Member 1

0 / 0

0%

0 / 0

0%
Proveca 1

0 / 0

0%

0 / 0

0%
PsoBest 1

1 / 1

100%

0 / 0

0%
Psychiatric Hospital of Attica 2

0 / 2

0%

1 / 1

100%
Public Health Scotland (PHS) 1

0 / 1

0%

0 / 0

100%
Purdue Pharma 1

0 / 1

0%

1 / 1

100%
Queen's University Belfast 1

0 / 0

0%

0 / 0

100%
RABBIT-SpA 1

1 / 1

100%

0 / 0

100%
Recordati Rare Diseases 5

0 / 4

0%

0 / 0

100%
Red Española de Investigación en Patologías Infecciosas (REIPI) 1

0 / 0

0%

0 / 0

100%
Regeneron 10

4 / 10

40%

3 / 4

75%
Region Uppsala 1

1 / 1

100%

0 / 0

75%
Region of Southern Denmark 1

0 / 0

100%

0 / 0

75%
Regional Research Council Mid Sweden 1

0 / 1

0%

0 / 0

75%
Regione Lombardia 1

1 / 1

100%

0 / 1

0%
Research Council of Lithuania (RCL) 1

0 / 0

100%

0 / 0

0%
Research Foundation – Flanders (FWO) 1

0 / 1

0%

1 / 1

100%
Research for Patient Benefit (RfPB) 1

1 / 1

100%

0 / 1

0%
Research in Real Life (RIRL) 17

15 / 17

88.2%

6 / 16

37.5%
Respiratory Effectiveness Group (REG) 19

17 / 19

89.5%

0 / 16

0%
Rhythm Pharmaceuticals 1

0 / 0

89.5%

0 / 0

0%
Roxane Laboratories 1

1 / 1

100%

0 / 0

0%
Royster Society of Fellows 2

2 / 2

100%

1 / 1

100%
SF Group Srl 1

1 / 1

100%

1 / 1

100%
SMB Laboratoires 1

1 / 1

100%

1 / 1

100%
SOOFT italia 1

0 / 1

0%

0 / 1

0%
SOTIO Biotech 1

0 / 1

0%

0 / 0

0%
STD Pharmaceuticals 1

1 / 1

100%

1 / 1

100%
Safer and Faster Evidence-based Translation (SAFE-T) 1

0 / 1

0%

0 / 0

100%
Sandoz 10

4 / 10

40%

2 / 5

40%
Sandoz France 1

0 / 1

0%

0 / 0

40%
Sanofi 58

29 / 55

52.7%

27 / 33

81.8%
Sanofi Belgium 2

0 / 2

0%

1 / 2

50%
Sanofi Pasteur 4

2 / 3

66.7%

1 / 1

100%
Sanofi Pasteur MSD 2

1 / 2

50%

1 / 2

50%
Sanofi US 2

1 / 1

100%

1 / 1

100%
Santen 2

2 / 2

100%

0 / 1

0%
Santhera Pharmaceuticals 1

0 / 1

0%

0 / 1

0%
Scienta Lab 1

0 / 0

0%

0 / 0

0%
Senatsverwaltung Berlin 1

1 / 1

100%

0 / 1

0%
Servicio Navarro de Salud-Osasunbidea (SNS-O / Osasunbidea) 1

0 / 0

100%

0 / 0

0%
Shionogi 3

0 / 2

0%

0 / 0

0%
Shire 13

7 / 12

58.3%

7 / 7

100%
Singapore Ministry of Education (MOE) 1

0 / 0

58.3%

0 / 0

100%
Sintetica 1

0 / 1

0%

1 / 1

100%
Slovenian Research and Innovation Agency (ARIS) 1

0 / 1

0%

0 / 1

0%
Social Insurance Institution (SII / Kela) 1

1 / 1

100%

1 / 1

100%
Società Prodotti Antibiotici (SPA) 1

1 / 1

100%

1 / 1

100%
Société de Pneumologie de Langue Française (SPLF) 1

0 / 1

0%

0 / 0

100%
Soochow University (Suda) 1

0 / 1

0%

0 / 1

0%
Spanish Health Strategy Action 1

0 / 1

0%

0 / 0

0%
Spanish National Plan 1

0 / 0

0%

0 / 0

0%
Spanish Society of Hospital Pharmacists (SEFH) 1

0 / 0

0%

0 / 0

0%
Spark Therapeutics 1

0 / 0

0%

0 / 0

0%
Spectrum Therapeutics 1

0 / 0

0%

0 / 0

0%
St. Olav's University Hospital 1

0 / 1

0%

0 / 0

0%
Stada Arzneimittel 8

2 / 8

25%

1 / 4

25%
Stallergenes 5

0 / 5

0%

1 / 2

50%
Stallergenes Greer 1

0 / 1

0%

0 / 0

50%
Statens Serum Institut (SSI) 1

1 / 1

100%

0 / 0

50%
Stichting Astma Bestrijding 1

0 / 0

100%

0 / 0

50%
Strathmann 2

0 / 2

0%

0 / 2

0%
Sun Pharmaceutical Industries 3

2 / 3

66.7%

1 / 1

100%
Sunovion Europe 1

0 / 0

66.7%

0 / 0

100%
Swedish Asthma and Allergy Association 1

0 / 1

0%

0 / 0

100%
Swedish Heart Lung Foundation 1

0 / 1

0%

0 / 0

100%
Swedish Heart and Lung Association 1

0 / 1

0%

0 / 0

100%
Swedish Orphan Biovitrum 4

3 / 4

75%

3 / 4

75%
Swedish Research Council 2

1 / 2

50%

1 / 1

100%
Swedish Society of Medicine 1

1 / 1

100%

0 / 0

100%
Swiss National Science Foundation (SNSF) 1

0 / 0

100%

0 / 0

100%
Switzerland 1

0 / 1

0%

0 / 0

100%
SyriMed 1

0 / 1

0%

0 / 1

0%
TFS HealthScience 1

1 / 1

100%

0 / 1

0%
Takeda 72

26 / 68

38.2%

40 / 47

85.1%
Takeda France 1

0 / 1

0%

0 / 1

0%
Takeda Oncology 1

1 / 1

100%

1 / 1

100%
Target Pharma 1

0 / 0

100%

0 / 0

100%
Target RWE 1

1 / 1

100%

1 / 1

100%
Tecnifar 1

0 / 1

0%

0 / 0

100%
Tecnimede 1

0 / 1

0%

0 / 0

100%
Tenovus Scotland 2

2 / 2

100%

0 / 0

100%
Teofarma 1

1 / 1

100%

1 / 1

100%
Teva 40

11 / 36

30.6%

7 / 24

29.2%
Teva Netherlands 1

0 / 1

0%

0 / 1

0%
Teva UK 1

1 / 1

100%

1 / 1

100%
Teva US 1

1 / 1

100%

0 / 0

100%
The Dunhill Medical Trust 2

0 / 2

0%

0 / 0

100%
The Medicines Company 1

0 / 1

0%

1 / 1

100%
The Psoriasis Association 1

0 / 0

0%

0 / 0

100%
Theramex 1

1 / 1

100%

1 / 1

100%
Theramex Ireland 1

1 / 1

100%

1 / 1

100%
Theramex UK 2

2 / 2

100%

2 / 2

100%
TherapeuticsMD 1

0 / 0

100%

0 / 0

100%
Theratechnologies 1

0 / 1

0%

0 / 0

100%
Theravia 1

0 / 1

0%

0 / 0

100%
Three Lakes Foundation 1

1 / 1

100%

0 / 1

0%
Thriassion General Hospital 1

0 / 1

0%

1 / 1

100%
Tillomed Laboratories 1

1 / 1

100%

0 / 0

100%
Tommy's Charity 1

1 / 1

100%

0 / 0

100%
Trials@Home 1

0 / 0

100%

0 / 0

100%
UK Research and Innovation Industrial Strategy Challenge Fund (UKRI ISCF) 1

1 / 1

100%

0 / 0

100%
UNC Lineberger Comprehensive Cancer Center 1

1 / 1

100%

0 / 0

100%
Ultragenyx 2

0 / 1

0%

0 / 0

100%
Uni-Pharma A.B.E.E. 1

0 / 0

0%

0 / 0

100%
Union Chimique Belge (UCB) 18

8 / 17

47.1%

9 / 9

100%
Union Health 1

1 / 1

100%

1 / 1

100%
Unitaid 1

0 / 1

0%

0 / 0

100%
United States Department of Veterans Affairs (VA) 2

2 / 2

100%

0 / 0

100%
University Hospital Cologne 1

0 / 1

0%

0 / 0

100%
University Hospital Hradec Králové 2

0 / 1

0%

0 / 1

0%
University Hospital of Pisa 3

0 / 0

0%

0 / 0

0%
University Medical Center Groningen (UMCG) 1

1 / 1

100%

1 / 1

100%
University of Auckland 1

0 / 1

0%

0 / 0

100%
University of Bern 1

1 / 1

100%

0 / 1

0%
University of Bonn 2

1 / 1

100%

0 / 1

0%
University of Bordeaux 2

1 / 2

50%

0 / 2

0%
University of Bristol 1

0 / 1

0%

0 / 0

0%
University of Dundee 3

1 / 3

33.3%

0 / 0

0%
University of East Anglia (UEA) 1

1 / 1

100%

0 / 0

0%
University of Florence (UNIFI) 1

1 / 1

100%

1 / 1

100%
University of Florida College of Pharmacy 1

0 / 1

0%

1 / 1

100%
University of Naples Federico II 1

0 / 0

0%

0 / 0

100%
University of North Carolina at Chapel Hill Clinical and Translational Science Awards (UNC-CTSA) 1

1 / 1

100%

1 / 1

100%
University of Oxford 4

1 / 3

33.3%

0 / 2

0%
University of Southern Denmark (SDU) 4

4 / 4

100%

1 / 2

50%
University of Toulouse 1

0 / 1

0%

0 / 0

50%
University of Valladolid (Uva) 1

0 / 0

0%

0 / 0

50%
University of Verona (UNIVR) 1

1 / 1

100%

0 / 1

0%
Universitätsklinikum Erlangen 1

0 / 1

0%

0 / 0

0%
Université Claude-Bernard Lyon 1 (UCBL) 1

1 / 1

100%

0 / 1

0%
Utrecht University (UU) 4

1 / 3

33.3%

0 / 1

0%
VII Framework Programme (FP7) 10

5 / 9

55.6%

5 / 5

100%
Vall d'Hebron University Hospital 1

1 / 1

100%

0 / 1

0%
Veracyte 1

1 / 1

100%

0 / 1

0%
Verco S.A. 1

1 / 1

100%

1 / 1

100%
Versus Arthritis 1

1 / 1

100%

0 / 0

100%
Vertex Pharmaceuticals 4

4 / 4

100%

3 / 3

100%
Vestische Kinder- und Jugendklinik Datteln 1

1 / 1

100%

1 / 1

100%
Viatris 1

0 / 1

0%

0 / 0

100%
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) 2

1 / 2

50%

1 / 1

100%
ViiV Healthcare 26

22 / 26

84.6%

17 / 19

89.5%
Vintage Pharma 1

1 / 1

100%

0 / 0

89.5%
Vir Biotechnology 2

1 / 2

50%

0 / 2

0%
Volv Global 1

0 / 1

0%

0 / 0

0%
WH-Pharma s.r.o. 1

0 / 1

0%

0 / 0

0%
Wellcome Trust 1

1 / 1

100%

0 / 0

0%
Wockhardt 1

1 / 1

100%

1 / 1

100%
Xiangya Hospital 1

1 / 1

100%

0 / 1

0%
Zambon 3

2 / 3

66.7%

1 / 1

100%
Zambon France 1

1 / 1

100%

1 / 1

100%
Zentiva 2

0 / 2

0%

0 / 0

100%
Zogenix 3

0 / 2

0%

0 / 0

100%
Zydus Lifesciences 1

0 / 1

0%

0 / 1

0%
acis Arzneimittel 1

0 / 1

0%

0 / 0

0%
bene-Arzneimittel 1

0 / 1

0%

0 / 1

0%
bioCSL 2

2 / 2

100%

2 / 2

100%
bluebird bio 1

0 / 1

0%

0 / 0

100%
mibe 1

0 / 1

0%

0 / 0

100%
uniQure 1

0 / 1

0%

0 / 0

100%
ÚJV Řež 1

0 / 1

0%

0 / 0

100%